In PLoS Medicine, volume 3, issue 9: doi:10.1371/journal.pmed.0030346
The competing interests statement was incomplete and should have read: “Jean-Louis Vincent is the current chairman of the International Sepsis Forum, and a member of the steering committee of the Surviving Sepsis Campaign. His personal views do not necessarily reflect those of the other members of these committees. The Surviving Sepsis Campaign has received funding from Eli Lilly, Baxter, and Edwards. The International Sepsis Forum is currently sponsored by bioMérieux, Biosite, Brahms Diagnostics, EBI, Eli Lilly Corporation, Eisai Global Clinical Development, GlaxoSmithKline, Novo Nordisk, Roche Diagnostics, Spectral Diagnostics, Takeda, and Toray. The author declares that he has received grants and/or honorariums from AstraZeneca, Baxter, bioMérieux, Biosite, Brahms Diagnostics, Edwards LifeSciences, Eli Lilly Corporation, Eisai Global Clinical Development, GlaxoSmithKline, Novo Nordisk, Spectral Diagnostics, Takeda, Toray, and Wyeth.”
Citation:Vincent J-L (2006) Correction: Is the Current Management of Severe Sepsis and Septic Shock Really Evidence Based? PLoS Med 3(12): e543. doi:10.1371/journal.pmed.0030543
Published: December 26, 2006
Copyright: © 2006 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.